Literature DB >> 8384571

Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies.

D R Hill1, N Suman-Chauhan, G N Woodruff.   

Abstract

The autoradiographical distribution of [3H]gabapentin, the tritiated analogue of the novel anticonvulsant gabapentin (1-(aminomethyl)cyclohexaneacetic acid) was measured in rat brain. Binding to sections was uniformly inhibited by non-radioactive gabapentin and 3-isobutyl-gamma-aminobutyric acid (3-isobutyl-GABA). Specific gabapentin binding sites were unevenly distributed throughout the brain with the highest level being found in the outer layers of the cerebral cortex (38 +/- 7 fmol/mm2; n = 3) and the lowest amounts in the white matter. In the hippocampus, the distribution of the binding site paralleled the excitatory neuronal input with the highest levels of binding being measured in the outer layers of the dentate gyrus and in the dendritic regions of the CA1 pyramidal cell layer. The binding site appeared absent from the cell body region of granule and pyramidal cells. Lesions performed unilaterally in the striatum using quinolinic acid resulted in a marked loss of [3H]gabapentin binding sites as compared with sham-lesioned animals, suggesting the binding site was localized on neuronal cell bodies. These data complement and extend the results of experiments using [3H]gabapentin with homogenates of rat brain and show the discrete localization of this novel binding site in regions associated with excitatory amino acid input. The data do not support previous indications of an association of the gabapentin binding site and NMDA/glycine receptor complex.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8384571     DOI: 10.1016/0922-4106(93)90156-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  21 in total

1.  Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity.

Authors:  M J Field; R J Oles; L Singh
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  Pregabalin in the treatment of chronic pain: an overview.

Authors:  S Chiechio; M Zammataro; F Caraci; L Rampello; A Copani; A F Sabato; F Nicoletti
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 3.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2017-06-29

Review 4.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

5.  Comparison of the uptake of [3H]-gabapentin with the uptake of L-[3H]-leucine into rat brain synaptosomes.

Authors:  R J Thurlow; D R Hill; G N Woodruff
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

6.  Comparison of the autoradiographic binding distribution of [3H]-gabapentin with excitatory amino acid receptor and amino acid uptake site distributions in rat brain.

Authors:  R J Thurlow; D R Hill; G N Woodruff
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Gabapentin completely attenuated the acute morphine induced c-Fos expression in the rat striatum.

Authors:  Jamil Ahsan Kazi; Chen Fun Gee
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 8.  Gabapentin. A review of its pharmacological properties and clinical potential in epilepsy.

Authors:  Karen L Goa; Eugene M Sorkin
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 9.  CNS adverse events associated with antiepileptic drugs.

Authors:  Gina M Kennedy; Samden D Lhatoo
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Tri-partite complex for axonal transport drug delivery achieves pharmacological effect.

Authors:  Aaron G Filler; Garth T Whiteside; Mark Bacon; Martyn Frederickson; Franklyn A Howe; Miri D Rabinowitz; Alan J Sokoloff; Terrence W Deacon; Chris Abell; Raj Munglani; John R Griffiths; B Anthony Bell; Andrew M L Lever
Journal:  BMC Neurosci       Date:  2010-01-20       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.